NDC product
SIGNATURE CARE Childrens Multi Symptom Cold
NDC 21130-162 · SAFEWAY
Key facts
| Product NDC | 21130-162 |
|---|---|
| Proprietary name | SIGNATURE CARE |
| Nonproprietary name | Dextromethorphan Hydrobromide, Guaifenesin, and Phenylephrine Hydrochloride |
| Substances | DEXTROMETHORPHAN HYDROBROMIDE, GUAIFENESIN, PHENYLEPHRINE HYDROCHLORIDE |
| Dosage form | SOLUTION |
| Route | ORAL |
| Labeler | SAFEWAY |
| Product type | HUMAN OTC DRUG |
| Marketing category | OTC MONOGRAPH DRUG |
| Application number | M012 |
| Pharmacologic classes | Adrenergic alpha1-Agonists [MoA], Decreased Respiratory Secretion Viscosity [PE], Expectorant [EPC], Increased Respiratory Secretions [PE], Sigma-1 Agonist [EPC], Sigma-1 Receptor Agonists [MoA] and 3 more |
| Marketing start | Jan 16, 2026 |
| Listing certified through | Dec 31, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: